Aurion Biotech
aurionbiotech.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
News
Aurion Biotech completes enrollment in phase 3 ASTRA study of AURN001 for corneal edema secondary to corneal endothelial dysfunction Eye Care Network - Ophthalmology Times
Patient enrollment is complete in the the ASTRA phase 3 study AURN001 to treat corneal edema associated with corneal endothelial dysfunction.
Read more
Report
Aurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunction
Potential first-in-class regenerative cell therapy to restore corneal clarity and improve vision with a single procedure Ongoing U.S. pivotal trial to assess efficacy and safety of AURN001 compared to vehicle control Full enrollment reached across 12 U.S.
Read more
Report
Aurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunction
SEATTLE & CAMBRIDGE, Mass. & TOKYO, September 23, 2026--Aurion Biotech, Inc. ("Aurion Biotech"), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced
Read more
Report
Drug Discovery News: What Does it Take to Scale a Living Cell Therapy?
To read this article, you'll leave the Aurion Biotech site and be redirected to an external news or trade media source. Continue to Article The post Drug Discovery News: What Does it Take to Scale a Living Cell Therapy? appeared first on Aurion Biotech.
Read more
Report
Aurion Biotech to Highlight Momentum Across Upcoming Eye Bank and Ophthalmology Meetings in June
Seattle, WA; Cambridge, MA, and Tokyo, Japan - May 28, 2026 - Aurion Biotech, Inc. ("Aurion Biotech"), a commercial-stage regenerative cell therapy company dedicated to restoring vision, today announced that the company will present at the Eye Bank Associ
Read more
Report
Aurion Biotech to Highlight Momentum Across Upcoming Eye Bank and Ophthalmology Meetings in June
Read more
Report
Aurion Biotech to Give Oral Presentation on Regenerative Cell Therapy for Corneal Endothelial Disease at ASGCT 2026
Seattle, WA; Cambridge, MA; Tokyo, Japan - May 6, 2026 - Aurion Biotech, Inc. ("Aurion Biotech"), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced
Read more
Report
Aurion Biotech to Give Oral Presentation on Regenerative Cell Therapy for Corneal Endothelial Disease at ASGCT 2026
Read more
Report
Phase 1/2 CLARA study shows AURN001 improves BCVA compared with standard of care for corneal endothelial dysfunction
To read this article, you'll leave the Aurion Biotech site and be redirected to an external news or trade media source. Continue to Article The post Phase 1/2 CLARA study shows AURN001 improves BCVA compared with standard of care for corneal endothelial d
Read more
Report
Endothelial cell therapy may transform future of endothelial disease management
To read this article, you'll leave the Aurion Biotech site and be redirected to an external news or trade media source. Continue to Article The post Endothelial cell therapy may transform future of endothelial disease management appeared first on Aurion B
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Aurion Biotech over the last 12 months, by layer, with the share of postings for each.
Technologies in use
2
Postings analysed
3
Stack modernity
43/100
Cloud & platforms
GCP
Developer tools
CAPA
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$155k
Typical range
$79k – $202k
Open positions
7
6
Jobs
Middle
16.7%
Senior
66.7%
Principal
16.7%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Middle | 1 | $155k | $155k |
| Senior | 4 | $160k | $128k – $188k |
| Principal | 1 | $202k | $202k |
Highest paying role
Senior Principal Engineer, MSAT
$202k
Normalized to USD per year
People
Greg Kunst
Executive Officer, Director
Arnaud Lacoste
Executive Officer
David Rostov
Executive Officer
Jeannette Bankes
Director
Link William
Director
Patrick Lally
Director
Andrew Elbardissi
Director
Christine Mccauley
Director
Tom Frinzi
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
28/100
Slowing
Open positions
7
0 opened / 0 closed in 30 days
ATS activity
Every ~2 days
09/30/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
43% ▼
Industrial Engineering
29% ▲
Administrative
14% ▼
HR
14% ▲
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
1
Countries
1
Busiest office
Cambridge
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Cambridge
United States
Regional office
2 open roles 2 posted in 90 days 100% engineering 200-500 est. staff $155k Avg Salary
hires for Science & Research